GB Sciences Inc
GB Sciences, Inc., a plant-based research and biopharmaceutical drug development company. The company offers cannabis inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, cytokine release syndrome, stress… Read more
GB Sciences Inc (GBLX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.021x
Based on the latest financial reports, GB Sciences Inc (GBLX) has a cash flow conversion efficiency ratio of 0.021x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-124.30K) by net assets ($-5.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
GB Sciences Inc - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how GB Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
GB Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GB Sciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Strata Power Corp
PINK:SPOWF
|
0.015x |
|
ISETAN MITSUKOSHI H
BE:4HP
|
N/A |
|
BIDVEST
MU:NQL1
|
N/A |
|
QSX
BATS:QSX
|
N/A |
|
Decklar Resources Inc
PINK:DKLRF
|
0.054x |
|
MCNB Banks Inc
PINK:MKIN
|
N/A |
|
AMICUS THERA
BE:AM6
|
-0.128x |
|
Lithium Energi Exploration Inc
PINK:LXENF
|
-1.507x |
Annual Cash Flow Conversion Efficiency for GB Sciences Inc (2003–2024)
The table below shows the annual cash flow conversion efficiency of GB Sciences Inc from 2003 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-03-31 | $-5.31 Million | $-975.70K | 0.184x | -47.00% |
| 2023-03-31 | $-4.41 Million | $-1.53 Million | 0.346x | -66.90% |
| 2022-03-31 | $-1.78 Million | $-1.87 Million | 1.047x | -29.40% |
| 2021-03-31 | $-1.47 Million | $-2.19 Million | 1.483x | -97.07% |
| 2020-03-31 | $-88.49K | $-4.48 Million | 50.622x | +9499.10% |
| 2019-03-31 | $17.16 Million | $-9.24 Million | -0.539x | +31.26% |
| 2018-03-31 | $15.63 Million | $-12.25 Million | -0.784x | -47.36% |
| 2017-03-31 | $8.40 Million | $-4.47 Million | -0.532x | -129.46% |
| 2016-03-31 | $-1.97 Million | $-3.56 Million | 1.805x | +112.54% |
| 2015-03-31 | $246.34K | $-3.55 Million | -14.393x | -6926.81% |
| 2014-03-31 | $-1.01 Million | $-213.65K | 0.211x | +569.81% |
| 2013-03-31 | $-1.19 Million | $-37.45K | 0.031x | -60.02% |
| 2012-03-31 | $-1.23 Million | $-96.52K | 0.079x | -43.62% |
| 2011-03-31 | $-1.32 Million | $-183.66K | 0.140x | -79.31% |
| 2010-03-31 | $-802.18K | $-541.59K | 0.675x | +86.33% |
| 2009-03-31 | $-355.28K | $-128.73K | 0.362x | +329.07% |
| 2008-03-31 | $-216.33K | $-18.27K | 0.084x | -93.50% |
| 2007-03-31 | $-179.63K | $-233.34K | 1.299x | -57.83% |
| 2006-03-31 | $-103.38K | $-318.42K | 3.080x | +126.14% |
| 2005-03-31 | $28.82K | $-339.57K | -11.782x | -905.99% |
| 2004-03-31 | $-17.95K | $-26.24K | 1.462x | +123.42% |
| 2003-03-31 | $15.01K | $-93.65K | -6.241x | -- |